TAKHZYRO

Google image searchProduct monograph

Active ingredient

lanadelumab, 300 MG/2 ML

DIN: 02505614

Dosage form(s): SOLUTION

Route(s) of administration: SUBCUTANEOUS

Description: 2 ML PREFILLED SYRINGE

Schedule: Prescription / Schedule D

Company: TAKEDA CANADA INC

Date: 28-FEB-2022

ATC:

• B06 — OTHER HEMATOLOGICAL AGENTS (ATC, ATC/DDD, )
• B06A — OTHER HEMATOLOGICAL AGENTS (ATC, ATC/DDD)
• B06AC — Drugs used in hereditary angioedema (ATC, ATC/DDD)
• B06AC05 — LANADELUMAB (ATC/DDD)

Reference brand drug: Takhzyro

External Links for Takhzyro

Search on Google

• Takhzyro side effects
• Takhzyro dosage
• lanadelumab side effects
• lanadelumab dosage

Takeda Canada Inc

Go to Takeda website to see drug product details. Sometimes you can find takhzyro photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.